Jane Hankins is an Oncology physician affiliated with St. Jude Children's Research Hospital. OpenAlex indexes 405 publications with 7,805 citations (h-index 48); ClinicalTrials.gov lists 9 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
262 Danny Thomas Pl
Memphis, TN 381053678
Telephone
901-595-3006Registry record last updated 23 May 2016.
Clinical trials
- Universal Newborn Screening For Sickle Cell Disease In Mozambique
Sponsor: St. Jude Children's Research Hospital
- Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization
Sponsor: St. Jude Children's Research Hospital
- Re-Aiming at Hydroxyurea Adherence for Sickle Cell With mHealth
Sponsor: St. Jude Children's Research Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Agios Pharmaceuticals, Inc.Program year20253 payments
- Novo Nordisk IncProgram year20251 payment
- Chiesi USA, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
3 NIH research awards on record, funded 2010–2021 per NIH RePORTER. The latest:
- RE-aiming at Hydroxyurea Adherence for Sickle cell with mHealth (RE-HASH)
St. Jude Children'S Research Hospital
FY2021$638,420U01HL133996 - RE-aiming at Hydroxyurea Adherence for Sickle cell with mHealth (RE-HASH)
St. Jude Children'S Research Hospital
FY2020$678,736U01HL133996 - RE-aiming at Hydroxyurea Adherence for Sickle cell with mHealth (RE-HASH)
St. Jude Children'S Research Hospital
FY2019$793,859U01HL133996
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- CRISPR-Cas9 Editing of the <i>HBG1</i> and <i>HBG2</i> Promoters to Treat Sickle Cell Disease
New England Journal of Medicine
2023 - Pregnancy outcomes with hydroxyurea use in women with sickle cell disease
American Journal of Hematology
2022 - Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood
British Journal of Haematology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Jeffrey Towbin, MD
St. Jude Children's Research Hospital
Raul Ribeiro, MD
St. Jude Children's Research Hospital
Thomas Merchant, DO
St. Jude Children's Research Hospital
Alberto Pappo, MD
St. Jude Children's Research Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”